Lv1
10 积分 2023-07-10 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
14天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
14天前
已完结
Optimal decision‐making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival
3个月前
已完结
Rare adverse events in clinical trials: understanding the rule of three
3个月前
已完结
Guide to the statistical analysis plan
3个月前
已完结
Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response
3个月前
已完结
Optimal decision‐making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival
3个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
4个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
7个月前
已关闭
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
7个月前
已完结
皖公网安备34019202002308
